1 suspended. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Recurrence (1)
Brain Diseases (1) · Brain Neoplasms (1) · Brain Stem Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Disease Attributes (1) · Glioma (1) · Infratentorial Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1)
Nivolumab (1) · Temozolomide (1)
Washington University School of Medicine (1)
United States (1)
R01CA296813 (1)